These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30177475)

  • 21. Coronary bypass in a patient with hemophilia B, or Christmas disease. Case report.
    Tourbaf KD; Bettigole RE; Zizzi JA; Subramanian S; Andersen MN
    J Thorac Cardiovasc Surg; 1979 Apr; 77(4):562-9. PubMed ID: 311396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current management of hemophilia B: recommendations, complications and emerging issues.
    Franchini M
    Expert Rev Hematol; 2014 Oct; 7(5):573-81. PubMed ID: 25112898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs.
    Russell KE; Olsen EH; Raymer RA; Merricks EP; Bellinger DA; Read MS; Rup BJ; Keith JC; McCarthy KP; Schaub RG; Nichols TC
    Blood; 2003 Dec; 102(13):4393-8. PubMed ID: 12933577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant factor IX for the treatment of hemophilia B. Introduction.
    Thompson A
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):1-3. PubMed ID: 9565159
    [No Abstract]   [Full Text] [Related]  

  • 25. [Hemophilia B replacement therapy drugs].
    Yan H; Zeng F
    Sheng Wu Gong Cheng Xue Bao; 2016 Feb; 32(2):164-71. PubMed ID: 27382766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of a patient with factor IX deficiency (hemophilia B) with coronary bypass surgery.
    Scharfman WB; Rauch AE; Ferraris V; Burkart PT
    J Thorac Cardiovasc Surg; 1993 Apr; 105(4):765-6. PubMed ID: 8469013
    [No Abstract]   [Full Text] [Related]  

  • 27. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myocardial infarction during factor IX infusion in hemophilia B: case report and review of the literature.
    Najaf SM; Malik A; Quraishi AU; Kazmi K; Kakepoto GN
    Ann Hematol; 2004 Sep; 83(9):604-7. PubMed ID: 15205916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemophilia in Iran.
    Dorgalaleh A; Dadashizadeh G; Bamedi T
    Hematology; 2016 Jun; 21(5):300-10. PubMed ID: 26914731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Perioperative use of recombinant activated factor VII (rF VIIa) in a patient with hemophilia A having inhibitors].
    Kawasaki Y; Saeki N; Kawamoto M; Yuge O; Fujii T
    Masui; 2005 Aug; 54(8):926-8. PubMed ID: 16104555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Coronary artery bypass with extracorporeal circulation in a patient with hemophilia B].
    Bukowski JG; De Brux JL; Ganascia B; Cottineau C; Jacob JP
    Ann Fr Anesth Reanim; 1996; 15(3):304-6. PubMed ID: 8758585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.
    Windyga J; Abbuehl BE; Hafeman AE
    Expert Rev Hematol; 2014 Jun; 7(3):333-42. PubMed ID: 24832133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of 2 preparations of factor IX concentrate in the treatment of a patient with hemophilia B].
    den Ottolander GJ
    Ned Tijdschr Geneeskd; 1972 Jul; 116(30):1278-82. PubMed ID: 5041298
    [No Abstract]   [Full Text] [Related]  

  • 36. Coronary artery bypass surgery, angioplasty and long term anti-platelet treatment in a type B hemophilia patient.
    Pesaro AE; Gaz MV; Karbstein R; Perin M; Serrano CV; Damico E
    Clinics (Sao Paulo); 2009; 64(8):822-3. PubMed ID: 19690670
    [No Abstract]   [Full Text] [Related]  

  • 37. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX.
    Escobar MA; Tehranchi R; Karim FA; Caliskan U; Chowdary P; Colberg T; Giangrande P; Giermasz A; Mancuso ME; Serban M; Tsay W; Mahlangu JN
    Haemophilia; 2017 Jan; 23(1):67-76. PubMed ID: 27480487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant factor IX.
    White GC; Beebe A; Nielsen B
    Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant coagulation factor approved for hemophilia B prophylaxis.
    Thompson CA
    Am J Health Syst Pharm; 2013 Aug; 70(15):1266. PubMed ID: 23867478
    [No Abstract]   [Full Text] [Related]  

  • 40. Perioperative Use of Coagulation Factor Concentrates in Patients Undergoing Cardiac Surgery.
    Smith MM; Ashikhmina E; Brinkman NJ; Barbara DW
    J Cardiothorac Vasc Anesth; 2017 Oct; 31(5):1810-1819. PubMed ID: 28838728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.